Wakefulness drug shows promise for brain tumor fatigue, but study stalls
NCT ID NCT03868943
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tested a drug called solriamfetol to see if it could safely help people with brain tumors (gliomas) feel more awake, think clearer, and have a better quality of life. Only 2 people enrolled before the study was stopped early. The main goal was to check for serious side effects, and the drug was also expected to improve sleepiness and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- A simple lotion duo may shield skin from Tumor-Treating fields